Skip to main content

Table 1 Patients information

From: Effects of nanomicelle curcumin capsules on prevention and treatment of oral mucosits in patients under chemotherapy with or without head and neck radiotherapy: a randomized clinical trial

Variable Study Control Significance (Chi-Square standardized statistic)
Sexuality    0.569 (0.32)
 Male 15 (60%) 13 (52%)  
 Female 10 (40%) 12 (48%)  
Age    0.396 (0.72)
 ≤ 56 14 (56%) 11 (44%)  
 > 56 11 (44) 14 (56%)  
Tumor type    0.994 (0.34)
 SCC 5 (20%) 5 (20%)  
 Lymphoma 3 (12%) 3 (12%)  
 Adenocarcinoma 9 (36%) 7 (28%)  
 Liemiosarcoma 1 (4%) 2 (8%)  
 Hepatocellular carcinoma 1 (4%) 1 (4%)  
 Angiosarcoma 1 (4%)  
 breast Ductal carcinoma 2 (8%) 3 (12%)  
 breast Lobular carcinoma 1 (4%) 1 (4%)  
 Ovarian carcinoma 2 (8%) 3 (12%)  
Tumor location    0.951 (0.05)
 Rectum 7 (28%) 6 (24%)  
 Ovary 2 (8%) 3 (12%)  
 Gastric 3 (12%) 3 (12%)  
 Breast 3 (12%) 4 (16%)  
 Liver 2 (8%) 1 (4%)  
 Colon 1 (4%) 2 (8%)  
 Larynx 2 (8%) 3 (12%)  
 Hypo-pharynx 2 (8%) 2 (8%)  
 Palate 2 (8%) 1 (4%)  
 Lymphoma in neck 1 (4%)  
Chemotherapy drug and dosage    0.999 (0.23)
 Cisplatin 30 2 (11.1%) 1 (5.3%)  
 Cisplatin 50 8 (44.4%) 9 (47.3%)  
 5FU 640 5 (27.7%) 6 (31.6%)  
 5FU 700 1 (5.6%) 2 (10.5%)  
 5FU 750 2 (11.1%) 1 (5.3%)  
Radiotherapy dosage    0.095
 6000 cGy 5 (71.5%) 1 (16.7%)  
 6600 cGy 0 1 (16.7%)  
 7000 cGy 2 (28.5%) 4 (66.6%)